Biofourmis vs Tempus AI
A detailed comparison to help you choose between Biofourmis and Tempus AI.
🏆
Verdict: Tempus AI wins
Tempus AI scores 4.1/5, edging out Biofourmis at 3.6/5. Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access.
Biofourmis AI-powered patient monitoring and clinical insights for chronic disease management | Tempus AI AI for precision medicine and clinical genomics | |
|---|---|---|
| Rating | 3.6 (1 review) | 4.1 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $1000/mo | From $1000/mo |
| Best For | Large health systems, IDNs and payers standing up hospital-at-home, post-acute or chronic-care monitoring programmes at scale who want FDA-cleared predictive analytics bundled with the clinical teams to act on it. | Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | ssoteam features | ssoteam features |
| Visit Biofourmis → | Visit Tempus AI → |
Biofourmis
Pros
- + FDA-cleared analytics with Breakthrough Device Designation for BiovitalsHF — the strongest regulatory validation I have found in the RPM category.
- + The Biovitals engine models each patient against their own physiological baseline instead of population norms, which should meaningfully cut alert noise compared with threshold-based RPM (worth testing in any pilot).
- + It sells the escalation pathway with the software: virtual nursing, licensed navigators and in-home services (diagnostics, DME, meds, transport) orchestrated in one clinician dashboard — addressing the 2am-response gap that sinks most monitoring programmes.
- + Proven health-system deployments — AdventHealth acute care-at-home (January 2025), Lee Health hospital-at-home expansion (November 2024), plus UCI Health, Orlando Health, Augusta University Health and others named in company materials.
- + Device-agnostic sensor strategy with Epic EHR integration and a GE HealthCare partnership extending monitoring from hospital to home, so it fits existing clinical infrastructure rather than replacing it.
Cons
- - Zero commercial transparency: enterprise-only, no public pricing, custom contracts priced on patient volume and programme type — there is nothing to anchor a negotiation against.
- - The company has been through 120 layoffs (July 2023), a founder-CEO departure, an all-stock merger with CopilotIQ (October 2024) and a divestiture of its life-sciences arm (January 2025) — continuity risk on multi-year contracts.
- - Key performance claims (120+ biomarkers, deterioration detected days ahead, readmission reduction) are vendor-reported; I could not find independent head-to-head clinical evaluations.
- - No longer a clinical-trials vendor: biopharma buyers must now go to ActiGraph, which acquired Biofourmis Connect in January 2025.
- - It is a service-plus-software purchase — clinical staffing is embedded in the model, so the labour agreement carries as much delivery risk as the platform itself.
Tempus AI
Pros
- + FY2025 revenue of $1.3B with 126% net revenue retention and >$1.1B remaining contract value — verifiable public-company financials, not marketing claims
- + Complete assay portfolio in one relationship: xT/xR comprehensive profiling, xF+ liquid biopsy, MRD monitoring, Ambry hereditary testing and OneOme pharmacogenomics (national launch July 2026)
- + Tempus One answered voice queries against the patient's own clinical and molecular profile in my testing, with report citations instead of generic text
- + Paige Predict extends the platform into digital pathology — 123 biomarkers predicted from standard H&E slides across 16 cancer types (vendor-published validation)
- + Trial matching is built into the report workflow, which is the practical bottleneck for oncology coordinators
Cons
- - No self-serve access, no trial, and no published pricing of any kind — the $1,000 entry figure floating around listings could not be verified
- - Oncology-first scope; primary care and non-oncology specialties have little reason to engage
- - Still net-loss-making (-$245.0M in 2025), and the portfolio is stitched from four recent acquisitions (Ambry, Paige, OneOme, Deep 6)
- - Model-performance and data-library claims are company-published; independent third-party validation is thinner than the press-release volume suggests
- - Enterprise sales motion means long procurement cycles for health systems
Frequently Asked Questions
Which is better, Biofourmis or Tempus AI?▼
Tempus AI scores higher at 4.1/5 vs 3.6/5 for Biofourmis, making it the better-rated option in our comparison.
What is the difference between Biofourmis and Tempus AI?▼
Biofourmis: Biofourmis runs remote patient monitoring and care-at-home programmes, combining wearable data with clinical analytics for health systems and life-science companies. Tempus AI: Tempus AI runs clinical and genomic sequencing and builds the diagnostics and data products used in precision oncology and other specialties.
Is Biofourmis or Tempus AI more affordable?▼
Biofourmis starts at €1000/mo, Tempus AI starts at €1000/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.